First of Three Patents Issued

February 17, 2020

Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system for delivering epinephrine to treat patients suffering from severe allergic reactions. This new approach will include a nasal delivery system containing a new formulation of epinephrine. This novel formulation is designed for nasal delivery and was a subject of a series of pre-clinical studies that provided the basis for three patent applications. The first of the patents have been issued, with the remaining two still pending.  Named on the patent are MSA Principals, Kenneth Dretchen, Ph.D., and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.

May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…

Read More

Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis

The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….

Read More

Mesa Science Associates and Bryn Pharma Publish Pre-Clinical Study of a New Approach to Treating Anaphylaxis

April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…

Read More